Novel Nomograms Based on Gamma-Glutamyl Transpeptidase-to-Lymphocyte Ratio Predict Prognosis of Hepatocellular Carcinoma Patients After Hepatectomy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322–330. doi:10.1097/00000658-199903000-00004
   PubMed Web of Science ®Google Scholar
• Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141(3):330–339. doi:10.1016/j.surg.2006.06.028
   PubMed Web of Science ®Google Scholar
• Chen ZH, Hong YF, Lin J, et al. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett. 2017;14(1):705–714. doi:10.3892/ol.2017.6222
   PubMed Web of Science ®Google Scholar
• Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91. doi:10.1159/000489791
   PubMed Web of Science ®Google Scholar
• Lim J, Singal AG. Surveillance and diagnosis of hepatocellular carcinoma. Clin Liver Dis. 2019;13(1):2–5. doi:10.1002/cld.761
   Google Scholar
• Giannini EG, Marenco S, Borgonovo G, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56(4):1371–1379. doi:10.1002/hep.25814
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289–312. doi:10.1016/j.bbcan.2019.01.005
   PubMed Web of Science ®Google Scholar
• Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7(2):242–254. doi:10.1007/s11684-013-0256-4
   PubMed Web of Science ®Google Scholar
• Hong YM, Yoon KT, Hwang TH, Cho M. Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. BMC Cancer. 2020;20(1):937. doi:10.1186/s12885-020-07105-8
   PubMed Web of Science ®Google Scholar
• Milito A, Brancaccio M, Lisurek M, Masullo M, Palumbo A, Castellano I. Probing the interactions of sulfur-containing histidine compounds with human gamma-glutamyl transpeptidase. Mar Drugs. 2019;17(12):650. doi:10.3390/md17120650
   PubMed Web of Science ®Google Scholar
• Jarcuska P, Janicko M, Drazilova S, et al. Gamma-glutamyl transpeptidase level associated with metabolic syndrome and proinflammatory parameters in the young Roma population in eastern Slovakia: a population-based study. Cent Eur J Public Health. 2014;22(Suppl):S43–S50. doi:10.21101/cejph.a3901
   PubMedGoogle Scholar
• Salman T, Kazaz SN, Varol U, et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: an Izmir oncology group study. Chemotherapy. 2016;61(6):281–286. doi:10.1159/000445045
   PubMed Web of Science ®Google Scholar
• Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology. 2013;2(11):e26468. doi:10.4161/onci.26468
   PubMed Web of Science ®Google Scholar
• Li S, Xu W, Liao M, et al. The significance of gamma-glutamyl transpeptidase to lymphocyte count ratio in the early postoperative recurrence monitoring and prognosis prediction of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:23–33. doi:10.2147/JHC.S286213
   PubMed Web of Science ®Google Scholar
• Liao M, Qin W, Liao Y, Yao R, Yu J, Liao W. Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with single tumor size ≤ 5 cm hepatocellular carcinoma after radical resection. Front Oncol. 2019;9:347. doi:10.3389/fonc.2019.00347
   PubMed Web of Science ®Google Scholar
• Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220(4):416–427. doi:10.1016/j.jamcollsurg.2014.12.025
   PubMed Web of Science ®Google Scholar
• Ma L, Deng K, Zhang C, et al. Nomograms for predicting hepatocellular carcinoma recurrence and overall postoperative patient survival. Front Oncol. 2022;12:843589. doi:10.3389/fonc.2022.843589
   PubMed Web of Science ®Google Scholar
• Qin YL, Wang S, Chen F, et al. Prediction of outcomes by diffusion kurtosis imaging in patients with large (>/=5 cm) hepatocellular carcinoma after liver resection: a retrospective study. Front Oncol. 2022;12:939358. doi:10.3389/fonc.2022.939358
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-1247133
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Jia Z, Yan Y, Wang J, et al. Development and validation of prognostic nomogram in ependymoma: a retrospective analysis of the SEER database. Cancer Med. 2021;10(17):6140–6148. doi:10.1002/cam4.4151
   PubMed Web of Science ®Google Scholar
• Tang X, Zhou X, Li Y, et al. A novel nomogram and risk classification system predicting the cancer-specific survival of patients with initially diagnosed metastatic esophageal cancer: a SEER-based study. Ann Surg Oncol. 2019;26(2):321–328. doi:10.1245/s10434-018-6929-0
   PubMed Web of Science ®Google Scholar
• Yu Y, Tan Y, Xie C, et al. Development and validation of a preoperative magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with early-stage breast cancer. JAMA Netw Open. 2020;3(12):e2028086. doi:10.1001/jamanetworkopen.2020.28086
   PubMed Web of Science ®Google Scholar
• Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–1916. doi:10.1053/j.gastro.2008.02.091
   PubMed Web of Science ®Google Scholar
• Franssen B, Alshebeeb K, Tabrizian P, et al. Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg. 2014;260(4):650–6;discussion 656–8. doi:10.1097/SLA.0000000000000917
   Web of Science ®Google Scholar
• Huitzil-Melendez FD, Capanu M, O’Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28(17):2889–2895. doi:10.1200/JCO.2009.25.9895
   PubMed Web of Science ®Google Scholar
• Chun YH, Kim SU, Park JY, et al. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47(17):2568–2575. doi:10.1016/j.ejca.2011.07.002
   PubMed Web of Science ®Google Scholar
• Satala CB, Jung I, Kobori L, et al. Benefits of the 8th American joint committee on cancer system for hepatocellular carcinoma staging. J Gastrointest Cancer. 2021;52(1):243–248. doi:10.1007/s12029-020-00394-z
   PubMed Web of Science ®Google Scholar
• Fu YP, Yi Y, Huang JL, et al. Prognostic nomograms stratify survival of patients with hepatocellular carcinoma without portal vein tumor thrombosis after curative resection. Oncologist. 2017;22(5):561–569. doi:10.1634/theoncologist.2016-0231
   PubMed Web of Science ®Google Scholar
• Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(3):121–127. doi:10.5152/dir.2018.17467
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi:10.1245/s10434-019-07227-9
   PubMed Web of Science ®Google Scholar
• Fukami Y, Kaneoka Y, Maeda A, et al. Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey. Ann Surg. 2020;272(1):145–154. doi:10.1097/SLA.0000000000003192
   PubMed Web of Science ®Google Scholar
• Huang WJ, Jeng YM, Lai HS, Sheu FY, Lai PL, Yuan RH. Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma. Langenbecks Arch Surg. 2015;400(6):725–734. doi:10.1007/s00423-015-1329-4
   PubMed Web of Science ®Google Scholar
• Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg. 2016;151(4):356–363. doi:10.1001/jamasurg.2015.4257
   PubMed Web of Science ®Google Scholar
• Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32(7):1053–1063. doi:10.1111/j.1478-3231.2012.02792.x
   PubMed Web of Science ®Google Scholar
• Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 2013;11:212. doi:10.1186/1477-7819-11-212
   PubMed Web of Science ®Google Scholar
• Kang SH, Kim DY, Jeon SM, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol. 2012;24(7):849–856. doi:10.1097/MEG.0b013e3283535c34
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang ZX, Cao Y, Zhang G, Chen WB, Jiang CP. Preoperative inflammation-based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int. 2016;15(3):266–274. doi:10.1016/S1499-3872(16)60094-2
   PubMed Web of Science ®Google Scholar
• Shen J, Liu J, Li C, Wen T, Yan L, Yang J. The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. J Viral Hepat. 2018;25(9):1057–1065. doi:10.1111/jvh.12911
   PubMed Web of Science ®Google Scholar
• Kim SH, Choi SB, Lee JG, et al. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011;15(4):598–607. doi:10.1007/s11605-011-1452-7
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.7132
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Luo D, Li H, Hu J, et al. Development and validation of nomograms based on gamma-glutamyl transpeptidase to platelet ratio for hepatocellular carcinoma patients reveal novel prognostic value and the ratio is negatively correlated with P38MAPK expression. Front Oncol. 2020;10:548744. doi:10.3389/fonc.2020.548744
   PubMed Web of Science ®Google Scholar
• Tang ZY. Liver transplantation: a simple inflammation marker predicts liver cancer prognosis. Nat Rev Gastroenterol Hepatol. 2011;8(7):367–368. doi:10.1038/nrgastro.2011.105
   PubMed Web of Science ®Google Scholar
• Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103–141. doi:10.1016/B978-0-12-420117-0.00003-7
   PubMed Web of Science ®Google Scholar
• Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36(12):1723–1734. doi:10.1111/liv.13221
   PubMed Web of Science ®Google Scholar
• Xia J, Song P, Sun Z, Sawakami T, Jia M, Wang Z. Advances of diagnostic and mechanistic studies of gamma-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov Ther. 2016;10(4):181–187. doi:10.5582/ddt.2016.01052
   PubMedGoogle Scholar
• Zhang CH, Ni XC, Chen BY, Qiu SJ, Zhu YM, Luo M. Combined preoperative albumin-bilirubin (ALBI) and serum gamma-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection. J Cancer. 2019;10(20):4836–4845. doi:10.7150/jca.33877
   PubMed Web of Science ®Google Scholar
• Yang Z, Ye P, Xu Q, et al. Elevation of serum GGT and LDH levels, together with higher BCLC staging are associated with poor overall survival from hepatocellular carcinoma: a retrospective analysis. Discov Med. 2015;19(107):409–418.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Lin YX, Ye H, Xiong XZ, Li FY, Cheng NS. Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection. Int J Surg. 2016;36(Pt A):143–151. doi:10.1016/j.ijsu.2016.10.033
   PubMed Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, Kuhnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689–713. doi:10.1007/s00018-017-2686-7
   PubMed Web of Science ®Google Scholar
• Atanasov G, Dino K, Schierle K, et al. Immunologic cellular characteristics of the tumour microenvironment of hepatocellular carcinoma drive patient outcomes. World J Surg Oncol. 2019;17(1):97. doi:10.1186/s12957-019-1635-3
   PubMedGoogle Scholar
• Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A. Peritransplant lymphopenia is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2014;97(6):694–701. doi:10.1097/01.TP.0000437426.15890.1d
   PubMed Web of Science ®Google Scholar
• Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25(28):3704–3721. doi:10.3748/wjg.v25.i28.3704
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Rovesti G, Dadduzio V, et al. Impact of aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. HPB. 2021;23(6):915–920. doi:10.1016/j.hpb.2020.09.024
   PubMed Web of Science ®Google Scholar
• Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020;7(3):359–369. doi:10.1016/j.gendis.2020.02.002
   PubMed Web of Science ®Google Scholar